Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 10:42 PM
Ignite Modification Date: 2025-12-25 @ 8:12 PM
NCT ID: NCT00777335
Description: None
Frequency Threshold: 3.0
Time Frame: The period for collection and reporting of adverse events extends from the time the patient signs the informed consent form (even if the event is not considered to be related to the study drug) until 28 days after the last receipt of the study treatment.
Study: NCT00777335
Study Brief: Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Panobinostat Intra-venous (i.v.) None None None 1 2 2 2 View
Panobinostat Oral None None None 0 2 2 2 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Electrocardiogram T wave inversion NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA (13.1) View
Dyspnea NON_SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (13.1) View
Pleural Effusion NON_SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (13.1) View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Decreased appetite NON_SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA (13.1) View
Dizziness NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (13.1) View
Headache NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (13.1) View
Peripheral Motor Neuropathy NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (13.1) View
Dyspnoea NON_SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (13.1) View
Alopecia NON_SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (13.1) View
Petechiae NON_SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (13.1) View
Thrombocytopenia NON_SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders MedDRA (13.1) View
Abdominal Pain NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (13.1) View
Tachycardia NON_SYSTEMATIC_ASSESSMENT Cardiac disorders MedDRA (13.1) View
Constipation NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (13.1) View
Diarrhoea NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (13.1) View
Nausea NON_SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (13.1) View
Fatigue NON_SYSTEMATIC_ASSESSMENT General disorders MedDRA (13.1) View
Electrocardiogram QT prolonged NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA (13.1) View
Weight decreased NON_SYSTEMATIC_ASSESSMENT Investigations MedDRA (13.1) View
Dysgueusia NON_SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (13.1) View
Epistaxis NON_SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (13.1) View